Mean outcome | TF3+  | TF3+ EM only | TF3+ CM only |
---|---|---|---|
Baseline attributes | |||
 Age (IQR; SD) | 45.4 (37.2, 53.0; 11.48) | ||
 Proportion CM, % | 45.9 | – | – |
 MMDs (IQR) | 14.3 (9.0, 20.3) | 9.2 (8.2, 10.1) | 20.3 (17.9,2 2.8) |
5-year truncated time horizona | |||
 Proportion transforming, % | 15.2 | – | 15 |
 Age at transformation (yrs) (IQR) | 49.5 (46.5, 52.6) | – | 49.5 |
 Proportion resolving, % | 13.9 | ||
 Age at resolution (yrs) (IQR) | 52.9 (49.9, 56.0) | 52.8 | 53.0 |
 Days with migraine, eptinezumab | 643 | 426 | 899 |
 Days with migraine, BSC | 789 | 521 | 1,105 |
 Years on treatment, eptinezumab | 1.6 | 1.2 | 1.9 |
 Years on treatment, BSC | 0.4 | 0.3 | 0.4 |
 Proportion TEAE discontinuation, % (timing, yrs) (SD) | 4.3 (0.09) | 3.7 (0.08) | 5.1 (0.11) |
 Proportion other-cause discontinuation, % (timing, yrs) (SD) | 20.1 (0.20) | 16.0 (0.16) | 24.9 (0.25) |
 Proportion super-responding, % | 3.2 | 3.2 | 3.2 |
Lifetime horizon | |||
 Proportion transforming, % | 62.8 | – | 62.8 |
 Age at transformation (yrs) | 50.6 | – | 50.6 |
 Proportion resolving, % | 73 | ||
 Age at resolution (yrs) | 54.5 | 54.4 | 54.6 |
 Years with migraine from start of treatment, eptinezumab | 14.5 | 13.3 | 16.0 |
 Years with migraine from start of treatment, BSC | 16.0 | 15.7 | 16.3 |
 Days with migraine, eptinezumab | 2,886 | 2,198 | 3,699 |
 Days with migraine, BSC | 3,245 | 2,437 | 4,199 |
 Years on treatment, eptinezumab | 3.6 | 2.7 | 4.6 |
 Years on treatment, BSC | 0.4 | 0.3 | 0.4 |
 Proportion TEAE discontinuation, % (timing, yrs) (SD) | 10.7 (0.95) | 8.2 (0.71) | 13.7 (1.22) |
 Proportion other-cause discontinuation, % (timing, yrs) (SD) | 20.1 (0.20) | 16.0 (0.16) | 24.9 (0.25) |